The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Reflecting on the progress made in the treatment of MPNs over the past 20 years
Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, reflects on the significant progress made in the treatment of myeloproliferative neoplasms (MPNs) over the past 20 years. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The aggregate impact of all of these things going on at once is really, really impactful. We’re here in Orlando, and I think back to ASH’s past. And as I think back, you know, over 20 years ago, coming to ASH in Orlando, we had almost nothing for MPNs. There was one oral session. We talked about things like splenectomy and radiation therapy. Now we have arguably at least two dozen different drugs that are being discussed, everything from Phase IIIs to Phase Is in rationally designed approaches for the disease...
The aggregate impact of all of these things going on at once is really, really impactful. We’re here in Orlando, and I think back to ASH’s past. And as I think back, you know, over 20 years ago, coming to ASH in Orlando, we had almost nothing for MPNs. There was one oral session. We talked about things like splenectomy and radiation therapy. Now we have arguably at least two dozen different drugs that are being discussed, everything from Phase IIIs to Phase Is in rationally designed approaches for the disease. So I’m just excited by the breadth and the depth of what we’re seeing and excited to see what will be kind of the next thing after the approval of the JAK inhibitors beyond that investigative space, but what are the things that really are going to be able to be prescribed, you know, in hematologist offices in the near future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
